New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK
READING, England–(BUSINESS WIRE)–For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a... Read more.
Caranx Medical (CarvOlix group) to Showcase Latest Updates at the 37th Annual Transcatheter Cardiovascular Therapeutics® Conference (TCT)
Company to highlight recently FDA cleared AI Software for real-time intraoperative guidance in Transcatheter Aortic Valve Implantation (TAVI) NICE, France–(BUSINESS... Read more.
Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal
LONDON–(BUSINESS WIRE)–Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks has been awarded a Platinum Medal,... Read more.
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced... Read more.
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in... Read more.
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage
LONDON & PARIS–(BUSINESS WIRE)–Lazard, Inc. (NYSE: LAZ) today announced the appointment of Edouard Panié as Managing Director and Co-Head of the... Read more.
Abyan Capital Launches Shariah-Compliant, Self-Directed Access to US Markets with Alpaca
NEW YORK & RIYADH, Saudi Arabia–(BUSINESS WIRE)–Abyan Capital, a leading robo-advisory investment platform in Saudi Arabia, today announced the launch... Read more.
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
– Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo – – IMvigor011 is the first global Phase... Read more.
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Data to be featured in Presidential Symposium at ESMO Signatera™ changes the paradigm by expanding the adjuvant decision window, with up to 7 tests in the first... Read more.
AM Best to Host Annual MENA Insurance Market Briefing in Dubai
LONDON–(BUSINESS WIRE)–#insurance—AM Best will host its annual Middle East and North Africa (MENA) market briefing on Tuesday, 25 November 2025,... Read more.